Skip to main content
Top
Published in: Trials 1/2022

Open Access 01-12-2022 | Study protocol

Effects of orthoptic therapy in children with intermittent exotropia after surgery: study protocol for a randomized controlled trial

Authors: Meiping Xu, Fuhao Zheng, Yiyi Peng, Chunxiao Wang, Jiangtao Lou, Huanyun Yu, Yuwen Wang, Xinping Yu

Published in: Trials | Issue 1/2022

Login to get access

Abstract

Background

Intermittent exotropia (IXT) is the most common type of exotropia in China. Surgery is usually required to align the eye deviation to maintain or obtain better binocular visual function. However, there is a high rate of exodrift or recurrence in surgically treated patients. Orthoptic therapy is sometimes recommended for IXT patients after surgery. However, there is a lack of high-quality randomized controlled trials to prove that orthoptic therapy could be an effective supplement to surgical treatment for IXT patients. The main purpose of this study is to test the clinical effectiveness of orthoptic therapy in long-term stabilization of postoperative IXT patient. This report describes the design and methodology of the Intermittent Exotropia Postoperative Treatment Clinical Trial, which is the first large-sample, blank-controlled, randomized clinical trial.

Methods

A total of 136 IXT patients (aged 7 to 17 years) will be enrolled and assigned to the orthoptic therapy group or blank control group according to a simple randomization scheme. Patients in the orthoptic therapy group will receive at least 2 months of orthoptic therapy, such as anti-suppression, vergence, and accommodation training. Patients in the blank control group will receive only refractive correction. All enrolled patients will need regular follow-up observation until 24 months after surgery. The primary outcome will be the proportion of participants meeting suboptimal surgical outcomes in this 24-month follow-up, which is defined as (1) exodeviation of 10 prism diopters (PD) at distance or near using the simultaneous prism and cover test (SPCT) or (2) loss of 2 or more octaves of stereoacuity from baseline, at any masked follow-up visit examination. The secondary outcomes will be the exodeviation at distance and near using the simultaneous prism and alternate cover test (PACT), magnitude of fusional convergence, stereoacuity, and accommodation. Measurements will be taken at baseline and at the 6-, 12-, 18-, and 24-month follow-ups.

Discussion

To the best of our knowledge, this will be the first prospective, randomized controlled study of orthoptic training in IXT patients after surgery. The aim of this work is to confirm the efficacy of orthoptic therapy in reducing the proportion of recurrence among IXT patients after surgery and improving binocular vision function.

Trial registration

Chinese Clinical Trial Registry ChiCTR1900026891​. Registered on 25 October 2019.
Literature
17.
go back to reference Singh V, Roy S, Sinha S. Role of orthoptic treatment in the management of intermittent exotropia. Indian journal of ophthalmology. 1992;40(3):83–5.PubMed Singh V, Roy S, Sinha S. Role of orthoptic treatment in the management of intermittent exotropia. Indian journal of ophthalmology. 1992;40(3):83–5.PubMed
22.
go back to reference Wu Y, Peng T, Zhou J, Xu M, Gao Y, Zhou J, et al. A survey of clinical opinions and preferences on the non-surgical management of intermittent exotropia in China. J Binocul Vis Ocul Motil. 2021;71(4):167–74.PubMed Wu Y, Peng T, Zhou J, Xu M, Gao Y, Zhou J, et al. A survey of clinical opinions and preferences on the non-surgical management of intermittent exotropia in China. J Binocul Vis Ocul Motil. 2021;71(4):167–74.PubMed
Metadata
Title
Effects of orthoptic therapy in children with intermittent exotropia after surgery: study protocol for a randomized controlled trial
Authors
Meiping Xu
Fuhao Zheng
Yiyi Peng
Chunxiao Wang
Jiangtao Lou
Huanyun Yu
Yuwen Wang
Xinping Yu
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-022-06246-4

Other articles of this Issue 1/2022

Trials 1/2022 Go to the issue